Drug Profile
Peginterferon alfa-2a biosimilar - Primrose Bio
Alternative Names: PF694Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
- Mechanism of Action Immunostimulants; Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 28 Jul 2018 No recent reports of development identified for preclinical development in Hepatitis-B in USA (SC, Injection)